Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma | MicrobiomeTrials← Back to trialsNCT07416188
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2026-06-14Est. Completion: 2030-12-31
Enrollment target: 40 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Glioblastoma Multiforme of BrainGliomaGlioblastoma
This is an open-label, multicenter dose-escalation study to be followed by a dose expansion to define the optimal dose o…
Tampa, United StatesEst. completion Jun 2027
Glioblastoma
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/…
Birmingham, United StatesEst. completion Jun 2028
GliomaGlioblastomas (GBM)High Grade Gliomas
The aim of this clinical trial is to evaluate the safety, preliminary effectiveness, and pharmacokinetic profiles of SM-…
Beijing, ChinaCompleted Apr 22, 2024